The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
CASMED Submits FORE-SIGHT® OEM Module 510(k) to FDA
Jan. 24, 2018 09:00AM PST
Medical Device InvestingCAS Medical Systems (NASDAQ:CASM) a leader in non-invasive cerebral oximetry patient monitoring, announces that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the FORE-SIGHT Tissue Oximetry OEM Module, an OEM version of its FORE-SIGHT ELITE® Tissue Oximeter. As quoted in the press release: “This filing is a major milestone …
CAS Medical Systems (NASDAQ:CASM) a leader in non-invasive cerebral oximetry patient monitoring, announces that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the FORE-SIGHT Tissue Oximetry OEM Module, an OEM version of its FORE-SIGHT ELITE® Tissue Oximeter.
As quoted in the press release:
“This filing is a major milestone for CASMED as we seek to make our best-in-class FORE-SIGHT oximetry technology available to manufacturers of other monitoring equipment,” said Thomas M. Patton, President and Chief Executive Officer of CASMED. “By partnering with third-party monitoring companies to incorporate FORE-SIGHT oximetry technology through the OEM Module, CASMED can leverage their selling resources to more quickly expand the market for tissue oximetry and gain market share.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.